| Document Date: 2014-02-12 15:27:02
Open Document File Size: 334,81 KBShare Result on Facebook
City SYMPOSIUM™ LEXINGTON / San Diego / / Company Synageva BioPharma Corp. / / / Event FDA Phase / Product Issues / / IndustryTerm biopharmaceutical company developing therapeutic products / drug product / manufacturing platform / / MedicalCondition mucopolysaccharidosis IIIB / accelerated atherosclerosis / LAL Deficiency LAL Deficiency / rare diseases / disease / rare autosomal recessive lysosomal storage disease / cirrhosis / Cholesteryl Ester Storage Disease / MPS IIIB The mucopolysaccharidoses / Wolman disease / diseases / deficiency / LAL Deficiency / B syndrome / / MedicalTreatment enzyme replacement therapy / biologic therapies / / Organization EMA / European Medicines Agency / U.S. Food and Drug Administration / FDA / Ministry of Health / / Person Sandra Rojas-Caro / MPS IIIB / Matthew Osborne / / / Position disease model / mouse model of MPS IIIB / Head / animal model / mouse model / Head of Clinical Research and Development / / Product SBC-103 / mice / / ProvinceOrState California / Massachusetts / / Technology alpha / / URL www.synageva.com / /
SocialTag |
SYNAGEVA BIOPHARMA™ HIGHLIGHTS SBC-103 DATA AT THE LYSOSOMAL DISEASE NETWORK (LDN) WORLD SYMPOSIUM™ LEXINGTON, Mass., February 12, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical compan